Bayer (BAYRY), the pharmaceutical and agricultural-science giant, cleared another legal hurdle after the Eighth Circuit rejected an objectors' challenge to its $7.25 billion Roundup settlement. The case now remains in Missouri state court, where Reuters said a review is scheduled for September 14. Shares stood at $14.10 on August 2884.8% above the $7.63 GF Value estimateshowing that investors are already pricing in a much stronger outcome than the valuation model suggests.

The headline number is enormous, but the math needs discipline. Bayer still faces roughly 65,000 US claims. A simple division puts the settlement at about $111,500 per existing claim, yet that figure is not a projected payout. The proposed structure covers both current and future cases, while legal costs, eligibility rules and individual allocations will shape the final economics.

This ruling advances the process. It does not finish the fight. Bayer still needs final approval and a framework strong enough to survive more objections while preventing the Roundup docket from rebuilding. After years of cash drain and management distraction, investors need lasting closurenot another temporary legal win. With the stock already trading far above GF Value, execution now carries even more weight.